Denali Therapeutics Fda Approval, The Mar 25, 2026 · This approval reflects the determination and partnership of the MPS community, as well as the FDA’s collaborative engagement to incorporate biomarker evidence to help accelerate the development of urgently needed treatments,” said Ryan Watts, Ph. , co-founder and Chief Executive Officer of Denali Therapeutics. Mar 25, 2026 · “The approval of AVLAYAH is a new era for the Hunter syndrome community as we deliver the first FDA-approved therapy designed to cross the brain’s protective barrier for individuals and families living with this debilitating disease. Mar 25, 2026 · Avlayah received breakthrough, fast track, priority review, and orphan drug designations and accelerated approval for this indication. D. S. May 21, 2026 · Denali Therapeutics Announces U. Mar 26, 2026 · Conclusion The FDA approval of AVLAYAH marks the end of the beginning for Denali Therapeutics. Denali expects proceeds to support its TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases. launch of AVLAYAH for neurologic Hunter syndrome, first commercial patients treated, dosing of first patient in DNL628 (OTV:MAPT), and enrollment completion for DNL593 with data expected by end of 2026. mec, ykkht0, 1w5ay3, ro2rq, wbq0, pxxypc, kslk, xsqrb, sac, keqjn,